China's Hansoh signs up to $1.45 billion deal for colorectal cancer drug with Roche

Reuters

Oct 17

UPDATE 1-China's Hansoh signs up to $1.45 billion deal for colorectal cancer drug with Roche

Adds further details from paragraph 2 onwards

Oct 17 (Reuters) - Chinese biotech Hansoh Pharma 3692.HK said on Friday it had signed a licence agreement worth up to $1.45 billion with Roche ROG.S for an investigational treatment of colorectal cancer and other solid tumours.

Hansoh Pharma units Shanghai Hansoh Biomedical and Changzhou Hansoh Pharmaceutical will grant Roche subsidiary F. Hoffmann-La Roche an exclusive worldwide licence to develop, manufacture and commercialise the product.

The licence excludes rights in the Chinese Mainland, Hong Kong, Macau and Taiwan.

The licensors will receive an upfront payment of $80 million and be eligible to receive up to $1.45 billion in milestone payments associated with the development, regulatory approval and commercialisation of the product, among others.

(Reporting by Sneha Kumar in Bengaluru; Editing by Shailesh Kuber and Subhranshu Sahu)

((Sneha.Kumar@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2576772937"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2576772937\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2576772937?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-17 07:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576772937","market":"us","top_or_hot":-1,"title":"China's Hansoh signs up to $1.45 billion deal for colorectal cancer drug with Roche","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>UPDATE 1-China's Hansoh signs up to $1.45 billion deal for colorectal cancer drug with Roche</title></head><body><p>Adds further details from paragraph 2 onwards</p><p><span>Oct 17 (Reuters)</span><span> - </span>Chinese biotech Hansoh Pharma <span>3692.HK</span> said on Friday it had signed a licence agreement worth up to $1.45 billion with Roche <span>ROG.S</span> for an investigational treatment of colorectal cancer and other solid tumours.</p><p>Hansoh Pharma units Shanghai Hansoh Biomedical and Changzhou Hansoh Pharmaceutical will grant Roche subsidiary F. Hoffmann-La Roche an exclusive worldwide licence to develop, manufacture and commercialise the product.</p><p>The licence excludes rights in the Chinese Mainland, Hong Kong, Macau and Taiwan.</p><p>The licensors will receive an upfront payment of $80 million and be eligible to receive up to $1.45 billion in milestone payments associated with the development, regulatory approval and commercialisation of the product, among others. </p><p> (Reporting by Sneha Kumar in Bengaluru; Editing by Shailesh Kuber and Subhranshu Sahu)</p><p> ((Sneha.Kumar@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China's Hansoh signs up to $1.45 billion deal for colorectal cancer drug with Roche</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina's Hansoh signs up to $1.45 billion deal for colorectal cancer drug with Roche\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-17 07:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>UPDATE 1-China's Hansoh signs up to $1.45 billion deal for colorectal cancer drug with Roche</title></head><body><p>Adds further details from paragraph 2 onwards</p><p><span>Oct 17 (Reuters)</span><span> - </span>Chinese biotech Hansoh Pharma <span>3692.HK</span> said on Friday it had signed a licence agreement worth up to $1.45 billion with Roche <span>ROG.S</span> for an investigational treatment of colorectal cancer and other solid tumours.</p><p>Hansoh Pharma units Shanghai Hansoh Biomedical and Changzhou Hansoh Pharmaceutical will grant Roche subsidiary F. Hoffmann-La Roche an exclusive worldwide licence to develop, manufacture and commercialise the product.</p><p>The licence excludes rights in the Chinese Mainland, Hong Kong, Macau and Taiwan.</p><p>The licensors will receive an upfront payment of $80 million and be eligible to receive up to $1.45 billion in milestone payments associated with the development, regulatory approval and commercialisation of the product, among others. </p><p> (Reporting by Sneha Kumar in Bengaluru; Editing by Shailesh Kuber and Subhranshu Sahu)</p><p> ((Sneha.Kumar@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nL6N3VX19N:1","article_id":"2576772937","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576772937","pubTimestamp":1760658183,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"UPDATE 1-China's Hansoh signs up to $1.45 billion deal for colorectal cancer drug with RocheAdds further details from paragraph 2 onwardsOct 17  - Chinese biotech Hansoh Pharma 3692.HK said on Friday it had signed a licence agreement worth up to $1.45 billion with Roche ROG.S for an investigational treatment of colorectal cancer and other solid tumours.Hansoh Pharma units Shanghai Hansoh Biomedical and Changzhou Hansoh Pharmaceutical will grant Roche subsidiary F. Hoffmann-La Roche an exclusive worldwide licence to develop, manufacture and commercialise the product.The licence excludes rights in the Chinese Mainland, Hong Kong, Macau and Taiwan.The licensors will receive an upfront payment of $80 million and be eligible to receive up to $1.45 billion in milestone payments associated with the development, regulatory approval and commercialisation of the product, among others.   ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","BK1583":"高瓴概念","BK1589":"北水核心资产","03692":"翰森制药"},"translate_title":"中国豪森与罗氏签署价值14.5亿美元的结直肠癌药物协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":0.9},"content_text":"UPDATE 1-China's Hansoh signs up to $1.45 billion deal for colorectal cancer drug with RocheAdds further details from paragraph 2 onwardsOct 17 (Reuters) - Chinese biotech Hansoh Pharma 3692.HK said on Friday it had signed a licence agreement worth up to $1.45 billion with Roche ROG.S for an investigational treatment of colorectal cancer and other solid tumours.Hansoh Pharma units Shanghai Hansoh Biomedical and Changzhou Hansoh Pharmaceutical will grant Roche subsidiary F. Hoffmann-La Roche an exclusive worldwide licence to develop, manufacture and commercialise the product.The licence excludes rights in the Chinese Mainland, Hong Kong, Macau and Taiwan.The licensors will receive an upfront payment of $80 million and be eligible to receive up to $1.45 billion in milestone payments associated with the development, regulatory approval and commercialisation of the product, among others.  (Reporting by Sneha Kumar in Bengaluru; Editing by Shailesh Kuber and Subhranshu Sahu) ((Sneha.Kumar@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}